Frail Patient With Frequent Falls and New-Onset NVAF

Canavero I, Micieli G, Paciaroni M. Decision algorithms for direct oral anticoagulant use in patients with nonvalvular atrial fibrillation: a practical guide for neurologists. Clin Appl Thromb Hemost. 2018;24:396-404.
Connolly BJ, Pearce LA, Hart RG. Vitamin K antagonists and risk of subdural hematoma: meta-analysis of randomized clinical trials. Stroke. 2014;45:1672-1678.
Connolly SJ, Crowther M, Eikelboom JW, et al; ANNEXA-4 Investigators. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med. 2019;380:1326-1335.
De Caterina R, Lip GYH. The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review. Clin Res Cardiol. 2017;106:565-572.
Diener HC, Aisenberg J, Ansell J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. Eur Heart J. 2017;38:860-868.
Diener HC, Bernstein R, Butcher K, et al. Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: expert opinion. Int J Stroke. 2017;12:9-12.
European Medicines Agency. Praxbind (idarucizumab): European public assessment report. https://www.ema.europa.eu/en/medicines/human/EPAR/praxbind. Published December 1, 2015. Updated August 13, 2020. Accessed August 25, 2020.
Fordyce CB, Hellkamp AS, Lokhnygina Y, et al. On-treatment outcomes in patients with worsening renal function with rivaroxaban compared with warfarin: insights from ROCKET AF. Circulation. 2016;134:37-47.
Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32:2387-2394.
Gage BF, Birman-Deych E, Kerzner R, et al. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med. 2005;118:612-617.
Giugliano RP, Ruff CT, Braunwald E, et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093-2104.
Glund S, Stangier J, Schmohl M, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet. 2015;386:680-690.
Hagerty T, Rich MW. Fall risk and anticoagulation for atrial fibrillation in the elderly: a delicate balance. Cleve Clin J Med. 2017;84:35-40.
Halperin JL, Hankey GJ, Wojdyla DM, et al; ROCKET AF Steering Committee and Investigators. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 2014;130:138-146.
Halvorsen S, Atar D, Yang H, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014;35:1864-72.
Hijazi Z, Hohnloser SH, Oldgren J, et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation. 2014;129:961-70.
Hohnloser SH, Fudim M, Alexander JH, et al. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and extremes in body weight: insights from the ARISTOTLE trial. 2019;139:2292-2300.
Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012;33:2821-2830.
Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115:2689-2696.
January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation. 2019;140:e125-e151.
Kermer P, Eschenfelder CC, Diener HC, et al. Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany - updated series of 120 cases. Int J Stroke. 2020;15:609-618.
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. 2016;18:1609-1678.
Lane DA, Lip GYH. Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. Circulation. 2012;126:860-865
Lee S, Choi E, Park CS, et al. Direct oral anticoagulants in patients with nonvalvular atrial fibrillation and low body weight. J Am Coll Cardiol. 2019;73:919-931.
Park CS, Choi EK, Kim HM, et al. Increased risk of major bleeding in underweight patients with atrial fibrillation who were prescribed non-vitamin K antagonist oral anticoagulants. Heart Rhythm. 2017;14:501-507.
Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess one year risk of major bleeding in atrial fibrillation patients: the Euro Heart Survey. Chest. 2010;138:1093-1100.
Pollack CV, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med Overseas Ed. 2015;373:511-520.
Pollack CV, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med. 2017;377:431-441.
PRADAXA® (dabigatran etexilate) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; Approved 2010. Revised July 2020.
Proietti M, Boriani G. Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal. Ther Clin Risk Manag. 2018;14:1483-1488.
Rao MP, Vinereanu D, Wojdyla DM, et al. Clinical outcomes and history of fall in patients with atrial fibrillation treated with oral anticoagulation: insights from the ARISTOTLE trial. Am J Med. 2018;131:269-275.e2.
Reed M, Tadi P, Nicolas D. Andexanet alfa. https://www.ncbi.nlm.nih.gov/books/NBK519499/. Updated July 8, 2020. Accessed August 25, 2020.
Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015;373:2413-2424.
Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016;5:e003725.
Zhu W, He W, Guo L, et al. The HAS-BLED score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation: a systematic review and meta-analysis. Clin Cardiol. 2015;38:555-561.

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Faculty

Sana M. Al-Khatib, MD, MHS

Professor of Medicine
Duke University Medical Center
Durham, North Carolina, United States

Disclosures

Disclosure: Sana M. Al-Khatib, MD, MHS, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Medtronic; Milestone Pharmaceuticals
Served as a speaker or a member of a speakers bureau for: Bristol Myers Squibb; Medtronic; Pfizer

Hans-Christoph Diener, MD, PhD

Professor of Neurology Emeritus
University Duisburg-Essen
Essen, Germany

Disclosures

Disclosure: Hans-Christoph Diener, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott; Bayer Vital; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi Sankyo; Medtronic; Pfizer; Portola; Sanofi Aventis
Served as a speaker or a member of a speakers bureau for: Abbott; Bayer Vital; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi Sankyo; Medtronic; Pfizer; Portola; Sanofi Aventis
Received grants for clinical research from: Bertelsmann Foundation; German Research Council; German Ministry of Education and Research; Heinz-Nixdorf Foundation; NIH

Editors

Lih-Fan Chang, MD, MPH

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Lih-Fan Chang, MD, MPH, has disclosed no relevant financial relationships.

Philippa M. Berman, BA (Hons), MBBS

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Philippa M. Berman, BA (Hons), MBBS, has disclosed no relevant financial relationships.

Kevan H. Chambers, CBiol, MRSB

Medical Writer, Medscape, LLC

Disclosures

Disclosure: Kevan H. Chambers, CBiol, MRSB, has disclosed no relevant financial relationships.

Content Reviewer

Esther Nyarko, PharmD

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott Labs

processing....

Legendas em português

« Return to: Episode 3: Frail Patient With Frequent Falls and New-Onset NVAF

Activity Transcript

References

Faculty and Disclosures

Faculty

Sana M. Al-Khatib, MD, MHS

Hans-Christoph Diener, MD, PhD

Editors

Lih-Fan Chang, MD, MPH

Philippa M. Berman, BA (Hons), MBBS

Kevan H. Chambers, CBiol, MRSB

Content Reviewer

Esther Nyarko, PharmD

Peer Reviewer

Episode 3: Frail Patient With Frequent Falls and New-Onset NVAF

Legendas em português